Lilburn

Researchers are studying the effects of a drug called KAI-9531, given as a subcutaneous injection once a week, in adults living with obesity or overweight who also have type 2 diabetes. The main goal is to see if KAI-9531 is better than a placebo at reducing body weight and lowering hemoglobin A1c (HbA1c), a measure of blood sugar control, over a 76-week period. This Phase 3, randomized, double-blind, placebo-controlled trial focuses on those who have tried and struggled to lose weight through diet and exercise. Participants receive either KAI-9531 or a placebo through weekly injections under the skin. The study compares doses 3 and 4 of KAI-9531 against placebo to evaluate changes in body weight and HbA1c from the start of the study to week 76. The treatment is monitored closely throughout the trial to assess effectiveness and safety. During the study, participants will have their body weight and HbA1c measured at baseline and again at week 76 to observe changes. Researchers will also monitor safety and any side effects. The overall participation includes regular follow-ups and assessments to track progress and health status over the study duration.

Researchers are evaluating the effects of KAI-9531, a weekly subcutaneous injection, on body weight changes in adults living with obesity or overweight who also have weight-related health conditions but do not have diabetes. This Phase 3, randomized, double-blind, placebo-controlled study aims to compare KAI-9531 against a placebo to understand its impact on weight reduction over time. Participants will receive either KAI-9531 or a placebo as a subcutaneous injection once a week. The study focuses on the percent change in body weight from the start of treatment to week 76. Both the treatment and placebo groups will be monitored throughout the trial to assess efficacy and safety. During the study, participants will have their body weight measured at baseline and week 76 to track changes. Researchers will also monitor safety and other health factors throughout the trial. The total participation duration includes the treatment period up to week 76, with assessments to evaluate the impact of the injections on weight and related health conditions.

Researchers are evaluating treatments for adults with psoriatic arthritis (PsA) who have not responded well to tumor necrosis factor inhibitors (TNFi). The study aims to compare switching to guselkumab, a selective interleukin 23 inhibitor, versus switching to another TNFi called golimumab. This Phase 3 trial tests whether changing to a new mechanism of action provides better results than trying a second TNFi, addressing an important question for patients with PsA who have inadequate responses to current therapy. Participants will receive either guselkumab or golimumab, both given as subcutaneous injections. The study is open-label and randomized, meaning both patients and researchers know which treatment is given, and patients are randomly assigned to one of the two options. The trial will observe patients over 12 months to assess treatment effectiveness. During the study, participants will have regular assessments including measuring disease activity with the clinical Disease Activity index for Psoriatic Arthritis (cDAPSA) and evaluating psoriasis severity. Researchers will monitor safety and treatment response through these measures and the Investigator Global Assessment of Psoriasis. The total participation duration is 12 months, allowing time to capture treatment effects and side effects.